Vertex Pharmaceuticals (NASDAQ: VRTX) has come a long way in the past ten years. In a little over a decade, the company has built a cystic fibrosis (CF) empire, commercializing four drugs for the disease that together generate blockbuster revenue . And the share price has soared more than 400%, scoring a big win for long-term investors.

Now, whether you're a Vertex investor or a potential one, you may be wondering what's next for this big biotech. The company recently started its expansion beyond CF with a U.K. regulatory nod for exa-cel, a gene-editing treatment for blood disorders. And Vertex has several candidates across treatment areas in the pipeline. Where will the company be in 10 years? Let's find out.

Image source: Getty Images.

Continue reading

Source Fool.com